Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Will Economic Incentives for Med. Institutions Be Effective to Promote Use of Generics?
December 22, 2008
- Commentary／Issue of Online Sales of OTC Drugs at Standstill
December 15, 2008
- COMMENTARY／Toyota, NEC Start Direct Inspection, Payment of Medical Bills
December 8, 2008
- COMMENTARY／Will VITAL KSK Become Core of Alliance of Regional Wholesalers?
December 8, 2008
- SURVEY／DPP-4 Inhibitors May Decrease Consumption of SUs
December 1, 2008
- COMMENTARY／Thinking about Why Megapharmas Are Closing Research Labs in Japan
November 24, 2008
- COMMENTARY／Marriage of Nos. 1 and 2 Wholesalers Creates Sensation in Market
November 3, 2008
- COMMENTARY／Competition Intensifies for Development of DPP-4 Inhibitors
September 22, 2008
- COMMENTARY／Yamato Searches for a Way to Start Generics Distribution Business
September 22, 2008
- COMMENTARY／Reform of Ethical Drug Distribution Practices
September 1, 2008
- COMMENTARY／Gov't to Cut Social Security Spending by \220 Bil by Promoting Use of Generics
August 25, 2008
- COMMENTARY／Development Race for RNAi Therapeutics Heating Up in Japan
August 4, 2008
- COMMENTARY 4 articles
July 28, 2008
- COMMENTARY／Industry Needs More Creative Thinking: NHI Pricing System Reform
July 21, 2008
- COMMENTARY／Will Fiscal Rehabilitation Policy Be Maintained?
July 7, 2008
- COMMENTARY／Daiichi Sankyo Surprises the World by Announcing Acquisition of Ranbaxy
June 30, 2008
- Pharmaceutical Partnerships in Japan for Regulatory and Commercial Success
June 30, 2008
- COMMENTARY 4 articles
June 9, 2008
- COMMENTARY／Shaking Pharmaceutical Administration System
May 19, 2008
- COMMENTARY／Personnel Strategy -New Graduates or Work-Ready MRs?
April 21, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…